Pharmaceutical Technology Editors

AbbVie grants Boehringer Ingelheim a non-exclusive license to its intellectual property for Humira (adalimumab) in the United States.

Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.

TraceLink will participate in the agency’s Pilot Project Program under the Drug Supply Chain Security Act.

The company announced plans to construct a 1.3 million-ft2 integrated manufacturing center in Chengdu, China.

The agency is reviewing Xeljanz (tofacitinib) because of the risk of blood clots in the lungs.

WHP has been awarded with the design contract for the United Kingdom’s first dedicated vaccines manufacturing innovation center (VMIC).

A “Darwinian” drug discovery program aimed at tackling cancer’s ability to develop drug resistance will launch in a new center based in London, United Kingdom.

The acquisition of GlaxoSmithKline’s manufacturing site in Cork, Ireland, will expand Thermo Fisher Scientific’s global footprint for complex API manufacturing.

A CPhI Middle East & Africa (MEA) expert has forecasted a boom in manufacturing in the region and has expectations that within five years some of the industry will be acting as contract manufacturers for the European market.

The Association of the British Pharmaceutical Industry has issued a response to the recently aired BBC Radio 4 investigation program on opioids.

Locate Bio has been granted additional investment to the tune of £2 million (US$2.6 million) for the expansion of its cell and gene therapy pipeline.

The European Medicines Agency has issued a vacancy notice for the position of executive director.

The partnership will focus on the commercialization of inducible promoters to improve biomanufacturing.

StarTab from Colorcon was designed to ensure functionality and stability for direct compression tableting.

The company is recalling the lots because of possible peanut flour contamination.

GE Healthcare launches Chronicle GMP-compliant automation software for cell therapy manufacturing.

The acquisition provides Valby, Denmark-based Lundbeck with a discovery platform and a US-based research hub.

The agency is warning these manufacturers that they are putting consumers at risk with substandard manufacturing practices.

The new 40,000-ft2 facility will support Bayer's growing biologics portfolio in oncology, cardiology, and additional therapeutic areas.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), awarded grants totaling $41.6 million to establish four cooperative research centers focused on developing vaccines to prevent sexually transmitted infections (STIs).

The acquisition will expand Pfizer’s rare disease portfolio with an early pipeline candidate for treating dwarfism.

Harvard University researchers used single-cell sequencing to identify a protein expressed uniquely by insulin-producing beta cells created from stem cells in the laboratory.

The UK government announced during the ABPI’s recent conference that it is making improvements to the Accelerated Access Collaborative.

A UK-based company, Atelerix, has revealed that it has closed a second round of funding worth £700,000 (US$911,000).

Shakespeare Martineau, a law firm, announced that advisers from the firm have assisted Bermele with a capital-raising move worth £1 million (US $1.3 million).

It has been confirmed that both Bulgaria and Cyprus will now be able to perform GMP inspections at a level considered equivalent to the United States

Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing for its specialist oncolytic virus and viral vector manufacturing services as a result of a growth in demand.

Research Point Global and WuXi Clinical Development Services have revealed that they are to combine and rebrand as a new CRO, WuXi Clinical.

EMA has launched a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.

Dyadic International has announced its collaboration agreement with Serum Institute of India for the development and manufacture of up to 12 antibodies and vaccines using Dyadic’s C1 gene expression system.